Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum

Table 2 Pooled CAMP-1 and CAMP-2 incidence and severity of TEAEs related to study drug (>1%)^a

See More TEAE^b incidence and severity	VP-102 (N = 311)			Vehicle (N = 216)
See More TEAE^b incidence and severity	Mild	Moderate	Severe	Mild	Moderate	Severe
Vesicles	187 (60.1)	100 (32.2)	11 (3.5)	59 (27.3)	4 (1.9)	0 (0.0)
Pruritus	145 (46.6)	23 (7.4)	1 (0.3)	62 (28.7)	13 (6.0)	0 (0.0)
Pain	127 (40.8)	59 (19)	7 (2.3)	34 (15.7)	2 (0.9)	0 (0.0)
Erythema	73 (23.5)	65 (20.9)	1 (0.3)	43 (19.9)	15 (6.9)	0 (0.0)
Scab	120 (38.6)	27 (8.7)	0 (0.0)	44 (20.4)	3 (1.4)	0 (0.0)
Discoloration	87 (28.0)	12 (3.9)	1 (0.3)	25 (11.5)	2 (0.9)	0 (0.0)
Dryness	58 (18.6)	5 (1.6)	0 (0.0)	30 (13.9)	1 (0.5)	0 (0.0)
Edema	21 (6.8)	8 (2.6)	0 (0.0)	7 (3.2)	3 (1.4)	0 (0.0)
Scar	7 (2.3)	1 (0.3)	0 (0.0)	5 (2.3)	0 (0.0)	0 (0.0)
Skin infection	0 (0.0)	1(.03)	0 (0.0)	0 (0.0)	3 (1.4)	0 (0.0)